Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Squire

Showing results (331-340 of 342) with videos related to

Pageof 35
Sort By:
Virchows Archiv : an International Journal of Pathology|February 11, 2016
In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgradingC G Picanço-Albuquerque, C L Morais, F L F Carvalho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapyJennifer A Locke, Gaetano Zafarana, Adrian S Ishkanian, et al.
Cancer|January 28, 2012
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapyGaetano Zafarana, Adrian S Ishkanian, Chad A Malloff, et al.
Nature Genetics|June 18, 2002
Mutations in SUFU predispose to medulloblastomaMichael D Taylor, Ling Liu, Corey Raffel, et al.
The Prostate|May 6, 2015
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancerDean A Troyer, Tamara Jamaspishvili, Wei Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinibMark Agulnik, Gilda da Cunha Santos, David Hedley, et al.
BMC Urology|September 12, 2018
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet, Armen Aprikian, Alain Bergeron, et al.
The Journal of Pathology|May 1, 2019
Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesisJuliana Y Sakita, Michael Bader, Emerson S Santos, et al.
Journal of the National Cancer Institute|March 5, 2020
Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)Tamara Jamaspishvili, Palak G Patel, Yi Niu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Pageof 35

Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
Virchows Archiv : an International Journal of Pathology|February 11, 2016
In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgradingC G Picanço-Albuquerque, C L Morais, F L F Carvalho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2011
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapyJennifer A Locke, Gaetano Zafarana, Adrian S Ishkanian, et al.
Cancer|January 28, 2012
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapyGaetano Zafarana, Adrian S Ishkanian, Chad A Malloff, et al.
Nature Genetics|June 18, 2002
Mutations in SUFU predispose to medulloblastomaMichael D Taylor, Ling Liu, Corey Raffel, et al.
The Prostate|May 6, 2015
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancerDean A Troyer, Tamara Jamaspishvili, Wei Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinibMark Agulnik, Gilda da Cunha Santos, David Hedley, et al.
BMC Urology|September 12, 2018
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet, Armen Aprikian, Alain Bergeron, et al.
The Journal of Pathology|May 1, 2019
Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesisJuliana Y Sakita, Michael Bader, Emerson S Santos, et al.
Journal of the National Cancer Institute|March 5, 2020
Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)Tamara Jamaspishvili, Palak G Patel, Yi Niu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Pageof 35